Commentary: Say goodbye to needles in next-generation COVID-19 vaccines
With the global pandemic causing the huge demand for vaccines, innovations could not only eliminate the prick we feel but also improve reliability, says a researcher.
MELBOURNE: The past 20 months has seen an explosion of vaccine development, with COVID-19 vaccine testing and rollout happening at an unprecedented pace in the face of a global pandemic.
There have been absolute triumphs – the fact we have multiple safe, effective vaccines is remarkable – but there have also been challenges.
We’ve seen storage and delivery issues, vaccine hesitancy, breakthrough infections and the beginnings of waning immunity.
Vaccine innovators around the world have these challenges in their sights. They are already working on the next generation of COVID-19 vaccines.
After hundreds of millions of doses, we have a good handle on how current vaccines are performing and where they can be improved.
As more data is gathered, a modified dose, time between doses, or using different vaccines together in mix-and-match strategies may become the preferred approach.
We could also improve vaccines that aren’t performing at their best.
Inactivated vaccines have been used in many parts of the world but their early protection has waned, particularly in older people, with the World Health Organization now recommending a third dose.
One way to improve this could be to add an adjuvant – something that fires up the immune system. One such vaccine, called Valneva, has early results that suggest including an adjuvant improves immunity.
MAKING VACCINATION EASIER AND NEEDLE-FREE
As we have seen, vaccinating large numbers of people is not easy. Innovations to make this easier will be welcome.
Needle-free approaches would be ideal. One approach, known as a nanopatch vaccine, coats the vaccine onto tiny spikes on a small patch.
The patch is applied to the skin and the spikes deliver the vaccine to a dense barrier of immune cells sitting just under the top layers of our skin.
A nanopatch COVID-19 vaccine, developed by Vaxxas and researchers in Queensland, Australia, has been shown to trigger strong immune responses in animal models, with trials underway in humans.
Another approach, known as an intranasal vaccine, sprays a vaccine up the nose. This would be easier to deliver and it could also build immunity in the right location in our body.
The coronavirus infects us through the lining of the nose, mouth, throat and lungs – a type of sticky tissue that lines body cavities and some organs called mucosa.
Currently, COVID-19 vaccines are delivered into our arm muscle and build antibody levels in our blood and tissue, with some antibody spilling out into the mucosa. Delivering the vaccine directly to the mucosa might be a better approach for preventing COVID-19 infection. This is being trialled with a number of vaccines, including the AstraZeneca vaccine.
Thinking about whether to get your booster shot? Listen to two infectious diseases experts break down the considerations on CNA's Heart of the Matter:
If yearly COVID-19 boosters are recommended for some or even all of the population, it would be easier to deliver them together with the yearly flu vaccine. These “multipathogen” vaccines are being tested with current flu vaccine or even new types of flu vaccine.
MORE DURABLE, CONSISTENT IMMUNITY
With two doses of the current vaccines, immunity is seen to decline and poor responses are seen in certain groups such as the severely immunecompromised and older people. COVID-19 vaccines that can induce more durable immunity and more consistently across vulnerable populations would be a major innovation.
This could require completely new vaccines. Protein subunit vaccines – which use purified protein from the surface of the virus as a target – are still working their way through approvals around the world.
One example is the Novavax vaccine but there are a large number of other protein subunit vaccines also developed that often use new adjuvants – again, the vaccine ingredient that fires up your immune system. These new adjuvants could support more durable immunity but this remains to be tested.
PROTECTION AGAINST FUTURE VARIANTS
We can also update the current vaccines by changing their target. All current COVID-19 vaccines use a target from the original strain of the coronavirus to train the immune system.
This is okay for vaccinating against the Delta variant, as it still looks pretty similar to the original virus to your immune system. But new variants could emerge that the immune system struggles to recognise.
We could simply use a new target from a new variant. Some vaccines have been updated to target the Beta variant, which is relatively hard for our immune system to recognise. Trials are being run with these Beta-targeted vaccines as a dry run, to make sure that we can update vaccines if we need to.
A more ambitious approach would be to focus the immune response on targets common to all coronaviruses. This “pan-coronavirus” vaccine would hopefully provide protection from all or most coronaviruses. Again, early data from animal models are promising.
VERIFYING WE ARE PROTECTED
An important innovation for COVID-19 vaccines would be an immune correlate.
An immune correlate is something that can be measured in an immune response to indicate if someone will be protected against infection or not. For rubella and hepatitis B virus, we measure the amount of antibody targeting these viruses in our blood. If antibody is absent or too low, a booster dose of the vaccine is recommended.
An immune correlate for COVID-19 could similarly allow us to identify people who need a booster.
Some researchers, including Australian teams, are sorting through data from around the world to see if there is something we can measure in our immune response to use as a correlate for COVID-19.
Research around the world is driving us towards the next generation of COVID-19 vaccines. Innovations for COVID-19 vaccines will lead to better vaccines for other infections too – those that currently afflict humanity and those that are yet to emerge.
Kylie Quinn is a research fellow at the Royal Melbourne Institute of Technology. This commentary first appeared at The Conversation.